Associations between cerebrospinal fluid biomarkers and cognition in early Untreated Parkinson's Disease

Journal of Parkinson's Disease

Volumn 5, Issue 4, 2015, Pages 783-792

  Skogseth, Ragnhild E ^a,b,j   Bronnick, Kolbjorn ^c,d   Pereira, Joana B ^e   Mollenhauer, Brit ^f   Weintraub, Daniel ^g   Fladby, Tormod ^h,i   Aarsland, Dag ^c,e  

^a STATOIL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF STAVANGER   (Norway)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h AKERSHUS UNIVERSITY HOSPITAL   (Norway)

ⁱ UNIVERSITY OF OSLO   (Norway)

^j Haraldsplass Deaconess Hospital   (Norway)

more..

Author keywords

alpha synuclein; amyloid beta peptides; cerebrospinal fluid; Mild cognitive impairment; Parkinson disease; tau Proteins

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT; SNCA PROTEIN, HUMAN;

ADULT; ARTICLE; ATTENTION; CEREBROSPINAL FLUID ANALYSIS; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEPTH PERCEPTION; EXECUTIVE FUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MIDDLE AGED; MOLECULAR DIAGNOSIS; PARKINSON DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN FUNCTION; PSYCHOLOGIC TEST; AGED; CEREBROSPINAL FLUID; CLINICAL TRIAL; COGNITIVE DYSFUNCTION; COHORT ANALYSIS; COMPLICATION; MULTICENTER STUDY;

AGED; ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; BIOMARKERS; COGNITIVE DYSFUNCTION; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 84952655835     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-150682     Document Type: Article

References (25)

1. Svenningsson P, Westman E, Ballard C, Aarsland D, 2012 Cognitive impairment in patients with Parkinson's disease: Diagnosis, biomarkers, and treatment. Lancet Neurol 11 697 707
2. Kehagia AA, Barker RA, Robbins TW, 2010 Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 9 1200 1213
3. Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, Lee VM, Leverenz JB, Montine TJ, Duda JE, Hurtig HI, Trojanowski JQ, 2012 Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 72 587 598
4. Kandiah N, Zainal NH, Narasimhalu K, Chander RJ, Ng A, Mak E, Au WL, Sitoh YY, Nadkarni N, Tan LC, 2014 Hippocampal volume and white matter disease in the prediction of dementia in Parkinson's disease. Parkinsonism Relat Disord 20 1203 1208
5. Compta Y, Parkkinen L, Kempster P, Selikhova M, Lashley T, Holton JL, Lees AJ, Revesz T, 2014 The significance of alpha-synuclein, amyloid-beta and tau pathologies in Parkinson's disease progression and related dementia. Neurodegener Dis 13 154 156
6. Gomperts SN, Locascio JJ, Rentz D, Santarlasci A, Marquie M, Johnson KA, Growdon JH, 2013 Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 80 85 91
7. Compta Y, Marti MJ, Ibarretxe-Bilbao N, Junque C, Valldeoriola F, Munoz E, Ezquerra M, Rios J, Tolosa E, 2009 Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord 24 2203 2210
8. Alves G, Bronnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E, 2010 CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: The Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 81 1080 1086
9. Leverenz JB, Watson GS, Shofer J, Zabetian CP, Zhang J, Montine TJ, 2011 Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism Relat Disord 17 61 64
10. Yarnall AJ, Breen DP, Duncan GW, Khoo TK, Coleman SY, Firbank MJ, Nombela C, Winder-Rhodes S, Evans JR, Rowe JB, Mollenhauer B, Kruse N, Hudson G, Chinnery PF, O'Brien JT, Robbins TW, Wesnes K, Brooks DJ, Barker RA, Burn DJ Group I-PS 2014 Characterizing mild cognitive impairment in incident Parkinson disease: The ICICLE-PD study. Neurology 82 308 316
11. Compta Y, Pereira JB, Rios J, Ibarretxe-Bilbao N, Junque C, Bargallo N, Camara A, Buongiorno M, Fernandez M, Pont-Sunyer C, Marti MJ, 2013 Combined dementia-risk biomarkers in Parkinson'sdisease: A prospective longitudinal study. Parkinsonism Relat Disord 19 717 724
12. Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, Shaw LM, Van Deerlin V, Trojanowski JQ, Clark C, 2010 CSF amyloid beta 1-42 predicts cognitive decline in Parkinsondisease. Neurology 75 1055 1061
13. Alves G, Lange J, Blennow K, Zetterberg H, Andreasson U, Forland MG, Tysnes OB, Larsen JP, Pedersen KF, 2014 CSF Abeta42 predicts early-onset dementia in Parkinson disease. Neurology 82 1784 1790
14. Parnetti L, Farotti L, Eusebi P, Chiasserini D, De Carlo C, Giannandrea D, Salvadori N, Lisetti V, Tambasco N, Rossi A, Majbour NK, El-Agnaf O, Calabresi P, 2014 Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson's Disease. Front Aging Neurosci 6 53
15. Hall S, Surova Y, Ohrfelt A, Zetterberg H, Lindqvist D, Hansson O, 2015 CSF biomarkers and clinical progression of Parkinson disease. Neurology 84 57 63
16. Stewart T, Liu C, Ginghina C, Cain KC, Auinger P, Cholerton B, Shi M, Zhang J, Parkinson Study Group DI 2014 Cerebrospinal fluidalpha-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol 184 966 975
17. Parkinson Progression Marker I 2011 The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 95 629 635
18. Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligorska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM, Parkinson's Progression Markers I 2013 Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70 1277 1287
19. Pereira JB, Svenningsson P, Weintraub D, Bronnick K, Lebedev A, Westman E, Aarsland D, 2014 Initial cognitive decline is associated with cortical thinning in early Parkinson disease. Neurology 82 2017 2025
20. Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M, 2012 Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 27 349 356
21. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, Zhang J, 2010 DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133 713 726
22. Randall C, Mosconi L, de Leon M, Glodzik L, 2013 Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly. Front Biosci (Landmark Ed) 18 1150 1173
23. Siepel FJ, Bronnick KS, Booij J, Ravina BM, Lebedev AV, Pereira JB, Gruner R, Aarsland D, 2014 Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease. Mov Disord 29 1802 1808
24. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA, 2009 The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 132 2958 2969
25. Roalf DR, Moberg PJ, Xie SX, Wolk DA, Moelter ST, Arnold SE, 2013 Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging. Alzheimers Dement 9 529 537